Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): What to Do When One Fails

How Vardenafil and Alprostadil Work: Two Entirely Separate Pathways

Vardenafil and alprostadil do not compete along the same biochemical route. Understanding the difference tells you immediately why one can succeed where the other fails.

Vardenafil (sold as Levitra in tablet form and Staxyn as an orally disintegrating tablet) blocks phosphodiesterase type 5, the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in smooth muscle cells of the corpus cavernosum. Higher cGMP relaxes smooth muscle and allows blood to fill the penis. The critical constraint: vardenafil only amplifies a signal that is already present. Sexual stimulation must trigger nitric oxide release from cavernous nerves for cGMP to accumulate in the first place. Men with significant nerve damage, radical prostatectomy, or severe autonomic neuropathy produce too little nitric oxide for vardenafil to amplify, regardless of dose. The FDA prescribing information for vardenafil makes this dependency explicit.

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP2 and EP3 receptors on cavernosal smooth muscle cells, directly elevating cyclic adenosine monophosphate (cAMP) through a G-protein coupled pathway that is entirely independent of nitric oxide. The erection does not require sexual stimulation. That independence is what makes alprostadil effective in neurogenic ED where PDE5 inhibitors fail.

Why This Mechanism Gap Matters Clinically

A man whose ED stems from cavernous nerve injury after prostatectomy will likely have inadequate nitric oxide synthesis. Vardenafil has nothing to amplify. Prescribing a higher vardenafil dose does not fix the underlying absence of signal. Switching to alprostadil injection (Caverject) bypasses that gap entirely.

Conversely, a man who avoids alprostadil because of needle anxiety or urethral discomfort but has intact cavernous nerves may do well on vardenafil with proper dose titration and optimized timing, factors that are frequently mismanaged in real-world practice. A 2003 observational analysis noted that a significant proportion of apparent PDE5 failures were actually suboptimal dosing or poor sexual stimulation conditions rather than true pharmacological non-response.

The Role of Endothelial Health

Both drugs depend to some degree on the vascular health of the penis. Severe arterial insufficiency from atherosclerosis can blunt the response to either agent, though alprostadil tends to retain more efficacy because its vasodilatory effect is more direct. Men with bilateral arterial occlusion severe enough to limit penile blood flow may see partial or no response to either drug and require vascular evaluation before escalating treatment.

Clinical Evidence for Each Drug

Head-to-head trials comparing vardenafil directly with alprostadil are limited. The evidence base for each drug is strong independently, and a few crossover studies offer practical comparison data.

Vardenafil Trial Evidence

The key Phase III trials for vardenafil showed consistent efficacy across ED etiologies. At 20 mg, vardenafil produced successful intercourse in approximately 65 to 80% of attempts versus 30 to 40% with placebo across multiple randomized controlled trials. The drug's selectivity for PDE5 over PDE6 (retinal phosphodiesterase) is approximately 10-fold greater than sildenafil, which translates to fewer visual side effects at therapeutic doses.

A 2003 study by Porst et al. evaluated vardenafil in a broad outpatient population with mixed ED etiologies. The investigators found that dose-optimization from 10 mg to 20 mg recovered response in a meaningful subset of men who reported initial failure at the lower dose, underscoring the importance of full dose escalation before switching agents.

Alprostadil Trial Evidence

The landmark clinical evidence for intracavernosal alprostadil was published by Linet et al. In the New England Journal of Medicine (1996). In a placebo-controlled trial of 296 men with chronic organic ED, alprostadil injection produced erections sufficient for intercourse in 94% of treated patients versus 0% of placebo, with a mean duration of 30 minutes. Penile pain was reported by approximately 37% of participants, but discontinuation due to pain was low at 3%.

The intraurethral (MUSE) formulation is less potent. Studies show successful intercourse rates of approximately 30 to 65% depending on dose (125 to 1,000 mcg) and patient selection, compared to over 80% for intracavernosal injection. Men who cannot tolerate injections often try MUSE first as a bridge option, though its efficacy is reliably lower than the injectable form.

Comparing Efficacy Head-to-Head

No single large randomized trial has directly randomized men to vardenafil versus intracavernosal alprostadil with a shared primary endpoint in a failure-crossover design. The available crossover data suggest that in men who fail oral PDE5 inhibitors, intracavernosal alprostadil rescues approximately 70 to 85% of them, depending on the underlying etiology. Post-prostatectomy patients respond at the lower end of that range due to nerve damage; men with psychogenic or mild vascular ED respond at the higher end.

When Vardenafil Fails: Defining True Failure vs. Suboptimal Use

"Failure" is over-diagnosed. Before switching to alprostadil, a prescriber should confirm that the vardenafil trial was adequate.

Criteria for an Adequate Vardenafil Trial

An adequate trial of vardenafil means:

• At least six attempts at the maximum tolerated dose (typically 20 mg for most men, or 5 to 10 mg for those on moderate CYP3A4 inhibitors)
• Drug taken 30 to 60 minutes before sexual activity on an empty or low-fat stomach (fatty meals delay absorption by up to 60 minutes)
• Adequate sexual stimulation during the observation window
• No concurrent nitrate use (which is an absolute contraindication, not a relative one)

The American Urological Association ED Guideline recommends confirming these conditions before escalating treatment. Many reported PDE5 inhibitor failures occur because men take the drug after a heavy meal, without stimulation, or at a subtherapeutic dose.

True Pharmacological Non-Response

If a man has completed an adequate trial as defined above and still cannot achieve penetration-sufficient erections, that is pharmacological non-response. This occurs most commonly in:

• Post-radical prostatectomy patients (non-nerve-sparing), where rates of PDE5 failure exceed 60%
• Men with diabetes mellitus complicated by autonomic neuropathy
• Men with severe penile arterial insufficiency
• Men on antihypertensives that reduce baseline blood pressure substantially

For these populations, the FDA-approved label for alprostadil injection (Caverject) explicitly positions it as effective in neurogenic, vasculogenic, psychogenic, and mixed-etiology ED, making it a logical next step regardless of why the PDE5 inhibitor failed.

When Alprostadil Fails: Defining True Failure vs. Dose or Technique Error

Alprostadil failure is less often a pharmacological non-response and more often a technique or dose problem.

Injection Technique and Dose Titration

Intracavernosal alprostadil must be injected correctly into the corpus cavernosum, not subcutaneously and not into the urethra. Off-target injection produces little or no erection and is misread as drug failure. The starting dose for Caverject is 2.5 mcg, with titration upward in 2.5 mcg increments under clinician supervision until a 30 to 45 minute erection is achieved. Many men are undertitrated, especially if the titration was done in an outpatient setting with limited follow-up.

The Linet et al. NEJM 1996 trial used in-office titration with physician supervision, which is likely why the 94% efficacy rate was achieved. Real-world efficacy without supervised titration is lower.

MUSE-Specific Failure Issues

MUSE (medicated urethral system for erections) requires the suppository to dissolve in the urethra and absorb across the urethral mucosa into cavernosal tissue. Common failure reasons include:

• Insufficient urethral lubrication (men should void before insertion to moisten the urethra)
• Inadequate post-insertion massage of the penis to distribute the drug
• Doses below the effective threshold for that individual (1,000 mcg is the ceiling dose)
• Anatomical barriers such as urethral stricture

If MUSE fails, that is not evidence that alprostadil itself fails. Caverject injection at a properly titrated dose should still be tried.

True Alprostadil Non-Response

Genuine non-response to intracavernosal alprostadil at doses up to 40 mcg (the maximum recommended dose) suggests severe cavernosal smooth muscle dysfunction or significant venous leakage (veno-occlusive dysfunction). A dynamic penile duplex ultrasound can distinguish between arterial insufficiency and veno-occlusive disease and guide further management, including possible penile prosthesis evaluation.

Combination Therapy: When to Use Both Together

Using vardenafil and alprostadil together is not a last resort. For selected patients, it may be the most rational first escalation step after a PDE5 inhibitor produces partial response.

The HealthRX Escalation Framework for ED Pharmacotherapy:

1. Oral PDE5 inhibitor (vardenafil or equivalent) at optimized dose with correct timing, minimum 6 attempts.
2. If partial response: add low-dose intraurethral alprostadil (MUSE 125 to 250 mcg) on the same encounter.
3. If MUSE augmentation insufficient: switch to intracavernosal alprostadil (Caverject 2.5 to 10 mcg) as monotherapy, titrated under supervision.
4. If intracavernosal monotherapy produces partial but inadequate erection: combine low-dose vardenafil (5 to 10 mg) with low-dose Caverject (5 to 10 mcg).
5. If combination pharmacotherapy fails at maximum tolerated doses: refer for penile duplex ultrasound and surgical prosthesis evaluation.

The combination approach has a pharmacological rationale. Vardenafil raises cGMP; alprostadil raises cAMP. Both second messengers independently relax cavernosal smooth muscle. Porst et al. (Int J Impot Res, 2003) demonstrated that combining sub-threshold doses of a PDE5 inhibitor with alprostadil produced erections in men who did not respond adequately to either agent alone at standard doses, and the combination allowed lower doses of each agent, reducing side effects.

The primary safety concern with combination therapy is prolonged erection (priapism). Both drugs independently carry priapism risk; combining them amplifies it. Men should be counseled to seek emergency care if an erection lasts more than 4 hours. A medic-alert card or written instruction sheet specifying the 4-hour threshold is standard practice at most sexual medicine centers.

Side Effect Profiles: A Practical Comparison

Side effects differ substantially between the two agents, and they often drive the choice more than efficacy data alone.

Vardenafil Side Effects

Vardenafil's most common adverse effects are headache (approximately 15%), flushing (11%), nasal congestion (9%), and dyspepsia (4%), based on pooled Phase III data cited in the FDA label. These are systemic effects from PDE5 inhibition in non-penile vascular beds. Vardenafil also prolongs the QTc interval at supratherapeutic doses, which led the FDA to add a caution regarding co-administration with Class IA and Class III antiarrhythmics. The orally disintegrating Staxyn formulation is not bioequivalent to Levitra tablets and should not be substituted on a milligram-for-milligram basis.

Alprostadil Side Effects

Alprostadil's dominant adverse effect is penile pain, reported by 37% of participants in the Linet NEJM trial. The pain is usually mild-to-moderate and diminishes with continued use as patients accommodate to the injection. Prolonged erection occurred in approximately 1% of men in clinical trials; this rate rises with dose escalation and combination use. Penile fibrosis and nodules are a long-term concern with repeated intracavernosal injections, occurring in 2 to 8% of chronic users. Limiting injection frequency to no more than three times per week and rotating injection sites reduces fibrosis risk. MUSE carries additional risks of urethral burning (32%), urethral bleeding (5%), and the rare complication of syncope from systemic hypotension, particularly in partners (vaginal absorption of alprostadil has been documented).

Contraindication Overlap

Both agents are contraindicated in men with conditions predisposing to priapism, including sickle cell disease, multiple myeloma, and leukemia. Vardenafil is absolutely contraindicated with any organic nitrate. Alprostadil has no nitrate interaction but is contraindicated in men with penile implants (the injection has no space to work in a prosthesis-implanted penis) and in sexual partners who are pregnant (MUSE formulation).

Special Populations: Post-Prostatectomy, Diabetes, and Cardiovascular Disease

Post-Prostatectomy ED

Penile rehabilitation after radical prostatectomy is an active area of clinical investigation. The rationale for early alprostadil use is that cavernosal oxygenation via regular erections (natural or pharmacologically induced) may reduce smooth muscle fibrosis and preserve erectile tissue pending nerve recovery. Several protocols use intracavernosal alprostadil 3 times per week starting within weeks of surgery, sometimes combined with a nightly oral PDE5 inhibitor. No single protocol has achieved definitive guideline-level evidence, but the physiological argument is sound and the practice is common in academic urology centers. The FDA label for Caverject includes neurogenic ED as an approved indication.

Diabetic ED

Men with diabetes have both neuropathic and vasculogenic components to their ED. PDE5 inhibitor response rates are lower in this group, approximately 50 to 60% versus 70 to 80% in non-diabetic men. Alprostadil retains efficacy in diabetic ED because it does not require intact nitric oxide signaling. A systematic review published in the Cochrane Database confirmed that intracavernosal alprostadil produces consistent erections in men with diabetic ED when appropriately titrated.

Cardiovascular Disease

Sexual activity is roughly equivalent to climbing two flights of stairs in cardiovascular demand. Most stable cardiac patients are cleared for sexual activity. Vardenafil is contraindicated with nitrates, which many cardiac patients take. In those men, alprostadil becomes the only safe oral-or-local ED option without stopping nitrates. The Princeton Consensus III guidelines stratify cardiovascular risk for sexual activity and guide which patients need cardiac evaluation before initiating any ED therapy. Men in the high-risk category require cardiology clearance regardless of which ED agent is selected.

Practical Switching Guide

Switching from vardenafil to alprostadil, or adding alprostadil to a vardenafil regimen, requires a few clinical steps that are often skipped in busy primary care settings.

Step 1: Rule out reversible causes of vardenafil failure. Check serum testosterone (free and total). Hypogonadism blunts PDE5 inhibitor response, and testosterone replacement alone or combined with vardenafil may restore function. Check thyroid function and prolactin if hypogonadism is not the explanation.

Step 2: Confirm the diagnosis of organic vs. Psychogenic ED. Psychogenic ED rarely warrants intracavernosal therapy as a first escalation. Cognitive-behavioral sex therapy combined with a PDE5 inhibitor often resolves psychogenic cases. If the IIEF (International Index of Erectile Function) score suggests severe organic ED, escalation to alprostadil is appropriate.

Step 3: In-office alprostadil titration. Do not send a patient home with Caverject without titrating in the clinic first. Start at 2.5 mcg, observe for 30 minutes, and document erection quality and any adverse effects. Titrate upward at subsequent visits until the target response is achieved.

Step 4: Provide written emergency instructions. Priapism is the most serious acute risk. The patient should have written instructions to go to an emergency department if erection persists beyond 4 hours. Pharmacological reversal with intracavernosal phenylephrine is the standard treatment per AUA guidelines.

Step 5: Schedule follow-up at 4 to 6 weeks. Confirm technique, check for early nodule formation, and reassess IIEF score to document response objectively.